The results are a “worst-case scenario” for Novo, said Markus Manns, portfolio manager at mutual funds firm Union Investment, a Novo and Lilly shareholder. Novo Nordisk CEO Lars Joergensen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback